Weekly Digest – September 2024 Weekly Digest – September 2024 11 Sep 2024: OS Therapies announces positive efficacy and safety data for ovarian cancer therapeutic candidate developed based on tunable antibody drug conjugate (tADC) platform using proprietary silicone linker platform […]
Weekly Digest – September 2024 Weekly Digest – September 2024 10 Sep 2024: Merck launches single-use reactor designed to accelerate antibody drug conjugate manufacturing The Mobius® ADC Reactor is the first scalable single-use mixer specifically designed for ADC manufacturing It […]
Weekly Digest – September 2024 Weekly Digest – September 2024 7 Sep 2024: Antibody-Drug Conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer Ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage […]
Weekly Digest – September 2024 Weekly Digest – September 2024 10 Sep 2024: AstraZeneca, Daiichi Sankyo’s Dato-DXd fails to significantly improve overall survival in phase III NSCLC The Phase III TROPION-Lung01 study showed datopotamab deruxtecan failed to significantly improve overall […]
Weekly Digest – September 2024 Weekly Digest – September 2024 10 Sep 2024: AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients Datopotamab deruxtecan demonstrated greater overall survival compared to docetaxel chemotherapy in the TROPION-Lung01 trial for NSCLC patients The […]
